Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Celcuity, Inc. (NASDAQ:CELC) have earned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $105.25.

Several analysts recently issued reports on the stock. Craig Hallum upped their price target on shares of Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Wells Fargo & Company started coverage on shares of Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price target on the stock. Needham & Company LLC set a $95.00 price target on Celcuity in a research note on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus lifted their target price on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 3,900 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the sale, the director owned 7,260 shares in the company, valued at $702,259.80. The trade was a 34.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.78% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently modified their holdings of the business. US Bancorp DE raised its stake in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the period. Rhumbline Advisers grew its holdings in shares of Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after purchasing an additional 503 shares during the last quarter. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Celcuity in the 3rd quarter worth approximately $27,000. Intech Investment Management LLC lifted its holdings in shares of Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock worth $198,000 after purchasing an additional 734 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the period. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Down 1.6%

NASDAQ:CELC opened at $99.92 on Wednesday. The stock has a market cap of $4.62 billion, a price-to-earnings ratio of -27.23 and a beta of 0.21. Celcuity has a one year low of $7.57 and a one year high of $112.64. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The business’s 50-day simple moving average is $91.86 and its 200 day simple moving average is $57.21.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. As a group, sell-side analysts predict that Celcuity will post -2.62 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.